Pulmatrix (PULM) Q3 2024 earnings summary

Executive summary

• Completed wind down of PUR1900 Phase 2b clinical trial and transferred commercialization responsibility outside the US to Cipla, with Pulmatrix retaining US rights and future royalties on ex-US sales.

• Executed MannKind Transaction, transferring facility lease, equipment, and most R&D staff to MannKind, resulting in a $2.6 million loss on asset disposal and significant reduction in operating costs.

• Closed transactions with MannKind Corporation, validating iSPERSE technology and improving balance sheet through cost-saving measures and repositioning as a virtual company.

• Focus remains on advancing PUR3100 (acute migraine) and PUR1800 (AECOPD) programs, contingent on securing additional funding or partnerships.

• Cash runway projected into Q4 2026, supporting ongoing operations and strategic initiatives.

Financial highlights

• Revenue for Q3 2024 was $0.4 million, down from $1.8 million in Q3 2023, due to the PUR1900 wind down; nine-month revenue rose to $7.8 million from $5.1 million, driven by a contract modification and catch-up adjustment.

• Q3 2024 net loss was $2.6 million, improved from $3.8 million in Q3 2023; net loss per share was $0.71 versus $1.03 year-over-year.

• Research and development expenses fell to $0.8 million in Q3 2024 from $4.0 million in Q3 2023, reflecting lower headcount and program costs.

• General and administrative expenses increased to $2.2 million in Q3 2024, mainly due to employee termination costs.

• Cash and cash equivalents totaled $10.8 million as of September 30, 2024.

Outlook and guidance

• Current cash is expected to fund operations for at least the next 12 months, with some projections extending into Q4 2026; additional funding or partnerships are required to advance clinical programs.

• Exploring financing or partnership arrangements to advance PUR3100 into Phase 2 clinical trials.

• Plans to monetize or partner PUR1800 and PUR1900, with ongoing royalty potential from Cipla for PUR1900 outside the US.

• Strategic alternatives and cost-saving measures are being considered, including further partnerships and licensing.